Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

IIVS News & Views

IIVS News & Views ATLA 34, 375, 2006 375 The Institute for In Vitro Sciences (IIVS) is a not-for- Toxicological Methods. In 2004, Dr Theran was profit organisation, dedicated to the advancement of appointed to the Institute of Laboratory Animal alternative test methods. IIVS seeks to refine the sci- Research Council. ence, broaden the use, and increase the worldwide acceptance of in vitro methods. To learn more about our organisation, please visit our website at www.iivs.org. IIVS Workshops and Activities Practical Methods Workshop in In Vitro Toxicology, held at IIVS on 13–15 June 2006, was a successful Reproducibility through Information forum for sharing information and ideas. Lectures were given by IIVS staff, as well as by invited speak- Exchange ers. Topics included established models such as the Bovine Corneal Opacity and Permeability Assay (pre- Interlaboratory reproducibility is a key component sented by Dr Joseph Sina of Merck Research), and in defining the usefulness and validity of an alterna- the In Vitro Percutaneous Absorption Assay (pre- tive assay system. Recognising this fact, IIVS and MB sented by Dr Robert Bronaugh, US FDA), as well as Research Laboratories (Spinnerstown, PA, USA) are new methods, such as the In Vitro Reconstituted engaged in an exchange of technical experience and Skin Micronucleus Assay (presented by Greg Mun, best practices for the Bovine Corneal Opacity and IIVS). During the afternoon session, the participants Permeability Assay. Over the past few months, the were teamed with IIVS laboratory personnel to gain two laboratories have cooperated to review documen- hands-on experience with specific assay systems. The tation, compare protocols and equipment, observe evenings were filled with opportunities for the par- the performance of the assay at each site, and per- ticipants to relax with each other and with members form concurrent evaluations of coded test materials. of the IIVS staff, resulting in a mutual exchange of Based on data generated and discussions between the ideas and a greater understanding of the role both scientists from both facilities, a harmonised protocol groups play in the advancement of alternative meth- will be developed and made available for use. The ods. protocol will standardise many procedures and ETS 2006 — The 6th International Conference on equipment requirements between the two laborato- Early Toxicity Screening was organised by the ries, assuring that data generated provide a consis- Institute for Scientific Exchange on 22–23 June tent evaluation for the ocular irritation potential of 2006, in Seattle, WA, USA. Hans Raabe presented a materials, regardless of the facility performing the talk entitled The Validation & Regulatory Acceptance assay. of In Vitro Toxicity/Potency Assays, which focused on the design and validation of in vitro bioassays intended for use in the regulated environment. He explained the concept that bioassays are designed IIVS Board of Directors around four components: a specific cell or tissue; defined exposure conditions; characterised endpoint IIVS is pleased to announce the addition of Peter measures of the biological effect; and a predeter- Theran DVM to its Board of Directors. As Vice mined relationship between the endpoint values and President of Animal Science for the Massachusetts the effect being predicted (potency or toxicity). An Society for the Prevention of Cruelty to Animals assay’s predictive capacity is dependent on maintain- (MSPCA), President of the Center for Laboratory ing consistency in these parameters from assay Animal Welfare, and national consultant in animal development and validation through to its routine welfare, Dr Theran’s primary focus is the welfare of use for regulatory submissions. animals in biomedical research, in consumer product safety testing, and in education. Dr Theran has served on numerous committees and boards of directors of organisations related to both animal welfare and research. He is a member of Publications the Board of Directors of Chimp Haven, a non-profit organisation dedicated to providing homes for chim- A paper entitled Development of a Method for Assessing Micronucleus Induction in a 3-D human panzees no longer needed in research, and of Public Skin Model (EpiDerm™), co-authored by scientists Responsibility in Medicine and Research (PRIM&R), from IIVS and the Procter & Gamble Company, has a research ethics organisation. From 1998 to the present, he has been a member of the ICCVAM been accepted for publication in Mutation Research, Scientific Advisory Committee on Alternative Genetic Toxicology and Environmental Mutagenesis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alternatives to Laboratory Animals SAGE

IIVS News & Views

Alternatives to Laboratory Animals , Volume 34 (4): 1 – Aug 1, 2006

Loading next page...
 
/lp/sage/iivs-news-views-dDqPD130jr

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
SAGE
Copyright
© 2006 Fund for the Replacement of Animals in Medical Experiments
ISSN
0261-1929
eISSN
2632-3559
DOI
10.1177/026119290603400406
Publisher site
See Article on Publisher Site

Abstract

ATLA 34, 375, 2006 375 The Institute for In Vitro Sciences (IIVS) is a not-for- Toxicological Methods. In 2004, Dr Theran was profit organisation, dedicated to the advancement of appointed to the Institute of Laboratory Animal alternative test methods. IIVS seeks to refine the sci- Research Council. ence, broaden the use, and increase the worldwide acceptance of in vitro methods. To learn more about our organisation, please visit our website at www.iivs.org. IIVS Workshops and Activities Practical Methods Workshop in In Vitro Toxicology, held at IIVS on 13–15 June 2006, was a successful Reproducibility through Information forum for sharing information and ideas. Lectures were given by IIVS staff, as well as by invited speak- Exchange ers. Topics included established models such as the Bovine Corneal Opacity and Permeability Assay (pre- Interlaboratory reproducibility is a key component sented by Dr Joseph Sina of Merck Research), and in defining the usefulness and validity of an alterna- the In Vitro Percutaneous Absorption Assay (pre- tive assay system. Recognising this fact, IIVS and MB sented by Dr Robert Bronaugh, US FDA), as well as Research Laboratories (Spinnerstown, PA, USA) are new methods, such as the In Vitro Reconstituted engaged in an exchange of technical experience and Skin Micronucleus Assay (presented by Greg Mun, best practices for the Bovine Corneal Opacity and IIVS). During the afternoon session, the participants Permeability Assay. Over the past few months, the were teamed with IIVS laboratory personnel to gain two laboratories have cooperated to review documen- hands-on experience with specific assay systems. The tation, compare protocols and equipment, observe evenings were filled with opportunities for the par- the performance of the assay at each site, and per- ticipants to relax with each other and with members form concurrent evaluations of coded test materials. of the IIVS staff, resulting in a mutual exchange of Based on data generated and discussions between the ideas and a greater understanding of the role both scientists from both facilities, a harmonised protocol groups play in the advancement of alternative meth- will be developed and made available for use. The ods. protocol will standardise many procedures and ETS 2006 — The 6th International Conference on equipment requirements between the two laborato- Early Toxicity Screening was organised by the ries, assuring that data generated provide a consis- Institute for Scientific Exchange on 22–23 June tent evaluation for the ocular irritation potential of 2006, in Seattle, WA, USA. Hans Raabe presented a materials, regardless of the facility performing the talk entitled The Validation & Regulatory Acceptance assay. of In Vitro Toxicity/Potency Assays, which focused on the design and validation of in vitro bioassays intended for use in the regulated environment. He explained the concept that bioassays are designed IIVS Board of Directors around four components: a specific cell or tissue; defined exposure conditions; characterised endpoint IIVS is pleased to announce the addition of Peter measures of the biological effect; and a predeter- Theran DVM to its Board of Directors. As Vice mined relationship between the endpoint values and President of Animal Science for the Massachusetts the effect being predicted (potency or toxicity). An Society for the Prevention of Cruelty to Animals assay’s predictive capacity is dependent on maintain- (MSPCA), President of the Center for Laboratory ing consistency in these parameters from assay Animal Welfare, and national consultant in animal development and validation through to its routine welfare, Dr Theran’s primary focus is the welfare of use for regulatory submissions. animals in biomedical research, in consumer product safety testing, and in education. Dr Theran has served on numerous committees and boards of directors of organisations related to both animal welfare and research. He is a member of Publications the Board of Directors of Chimp Haven, a non-profit organisation dedicated to providing homes for chim- A paper entitled Development of a Method for Assessing Micronucleus Induction in a 3-D human panzees no longer needed in research, and of Public Skin Model (EpiDerm™), co-authored by scientists Responsibility in Medicine and Research (PRIM&R), from IIVS and the Procter & Gamble Company, has a research ethics organisation. From 1998 to the present, he has been a member of the ICCVAM been accepted for publication in Mutation Research, Scientific Advisory Committee on Alternative Genetic Toxicology and Environmental Mutagenesis.

Journal

Alternatives to Laboratory AnimalsSAGE

Published: Aug 1, 2006

There are no references for this article.